Accuitis is a pharmaceuticals company targeting niche, orphan and underserved diseases. The company’s flagship product is a treatment for rosacea, based on intellectual property developed at Emory University.
The compound underlying the rosacea treatment is a proteasome inhibitor targeting the 26s proteasome. Blocking this proteasome inhibits NFkB, which is believed to play a significant role in skin diseases such as acne, rosacea and skin aging.
The worldwide dermatology market is expected to grow to $22.7 billion by 2017, driven by innovation in treating chronic diseases such as psoriasis. The combined estimated market potential for Accuitis’ compound is expected to exceed $500 million.
Company website: Accuitis